Search
Sunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalOn January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). … Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R).
Efgartigimod alfa
go.drugbank.com/drugs/DB15270ApprovedInvestigationalMyasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction … [L39509] By antagonizing this interaction, efgartigimod alfa prevents this recycling phase and thus decreases the half-life of IgG, effectively lowering circulating levels of IgG autoantibodies against
D-glucose
go.drugbank.com/drugs/DB01914ApprovedInvestigationalVet approvedGlucose is a simple sugar (monosaccharide) generated during phosynthesis involving water, carbon and sunlight in plants. It is produced in humans via hepatic gluconeogenesis and breakdown of polymeric glucose forms (glycogenolysis). It c...
Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE. … Glucarpidase is a recombinant carboxypeptidase G2 produced by genetically modified _Escherichia coli_ bacteria. It is a 390-amino acid homodimer protein.
Simethicone
go.drugbank.com/drugs/DB09512ApprovedInvestigational[A228308] Simethicone has been in use since the 1940s[A228303] but was granted FDA approval in 1952.[A228308]
Mixtures: DYNA-U TABLET, DYNA U SUSPENSIONResorcinol
go.drugbank.com/drugs/DB11085ApprovedInvestigationalResorcinol works by helping to remove hard, scaly, or roughened skin.
Mixtures: Up and up vagicaineSugammadex
go.drugbank.com/drugs/DB06206ApprovedInvestigationalSugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015. … Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery.
Potassium bicarbonate
go.drugbank.com/drugs/DB11098ApprovedInvestigationalIt is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid.
Mixtures: Neo K, POT-K 1,56 G EFERVESAN TABLET, 60 ADETProducts: K-effervescent, Effer-K OrangeLumefantrine
go.drugbank.com/drugs/DB06708ApprovedInvestigational</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.
Cysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigational[L15606] Cysteamine eye drops are a practical and effective option for those affected by ocular cystinosis. … A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys.